Henry Schein

Current directors and officers who also hold a role at another S&P 500 company.

• Frederick M. LoweryDD · DirectorTMO · Officer

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Oct 8, 2026

   On October 8, 2026, Henry Schein, Inc. (the “Company”) announced that (i) Ronald N. South will continue to serve as Senior Vice President and Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer through November 3, 2026, including through the completion of the Company’s third quarter earnings process, and effective November 4, 2026, Mr. South’s employment will transition to the role of Senior Advisor and (ii) the Board of Directors (the “Board”) approved the appointment of Emmanuel Caprais to initially serve as Senior Financial Advisor of the Company on October 12, 2026, allowing for a structured transition and onboarding period, and effective November 4, 2026 to serve as Senior Vice President, Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer.

   Read the 8-K filing
2. Jul 30, 2026

   (b) On July 30, 2026, Henry Schein, Inc. (the “Company”) announced that, effective October 30, 2026, Michael S. Ettinger, the Company’s Executive Vice President and Chief Operating Officer, and Mark E. Mlotek, the Company’s Executive Vice President and Chief Strategic Officer, will transition out of their current roles into senior advisory roles. In connection with such transition, Mr. Ettinger and Mr. Mlotek will be entitled to receive the payments and benefits under the Company’s Executive Severance Plan, in accordance with and subject to the terms and conditions of the plan.

   Read the 8-K filing
3. Jan 12, 2026

   Executive Leadership Changes On January 10, 2026, the Board of Directors (the “Board”) of Henry Schein, Inc. (the “Company”) appointed Mr. Frederick Lowery as Chief Executive Officer of the Company, effective March 2, 2026 (the “Effective Date”). In connection with Mr. Lowery’s appointment, the Board expanded the size of the Board from 14 to 15 members and appointed Mr. Lowery to fill the resulting vacancy, in each case, effective as of the Effective Date. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc.

   Read the 8-K filing
4. Dec 23, 2025

   On December 23, 2025, Henry Schein, Inc. (the “Company”) issued a press release announcing that its Board of Directors expects to name the Company’s next Chief Executive Officer by mid-January 2026 and that Stanley M. Bergman will continue in his role as CEO and Chairman of the Company until a successor CEO assumes the position. In connection with the announcement, the Company and Mr. Bergman entered into a letter agreement (the “Letter Agreement”) to extend Mr. Bergman’s Amended and Restated Employment Agreement dated as of November 28, 2022 by and between the Company and Mr. Bergman (the “Employment Agreement”) for a term through the earlier of (a) the date of commencement of employment of a new Chief Executive Officer of the Company and (b) the date following the thirtieth (30 th ) day after Mr.

   Read the 8-K filing
5. Sep 9, 2025

   (b) As previously disclosed on April 1, 2025, James Breslawski transitioned from the role of President of Henry Schein, Inc. (the “Company”) to Senior Advisor and member of the Company’s Executive Management Committee (“current role”). On September 5, 2025, Mr. Breslawski transitioned out of his current role. In connection with his transition, Mr. Breslawski will receive payments and benefits under the Company’s Executive Severance Plan.

   Read the 8-K filing
6. Jul 15, 2025

   (b) On July 15, 2025, Henry Schein, Inc. (the “Company”) announced that Stanley M. Bergman will retire as the Company’s Chief Executive Officer (“CEO”), effective December 31, 2025. Mr. Bergman will continue to serve as Chairman of the Board of Directors of the Company following his retirement.

   Read the 8-K filing
7. May 16, 2025

   On May 16, 2025, William K. “Dan” Daniel was appointed to the Company’s board of directors (the “ Board ”) as a director. The Board has determined that Mr. Daniel qualifies as an “independent director” as such term is defined in the rules and regulations of the Nasdaq Stock Market. In connection with Mr. Daniel’s appointment to the Board, the Company increased the size of the Board to 16 directors. In addition, the Company has also appointed Mr. Daniel to the Board’s Compensation Committee and to the Board’s Strategic Advisory Committee. Mr. Daniel has been appointed to the Board pursuant to the Partnership Agreement. Per the Partnership Agreement, Mr.

   Read the 8-K filing
8. May 2, 2025

   On May 2, 2025, Max Lin was appointed to the Company’s board of directors (the “ Board ”) as a director. The Board has determined that Mr. Lin qualifies as an “independent director” as such term is defined in the rules and regulations of the Nasdaq Stock Market. In connection with Mr. Lin’s appointment to the Board, the Company increased the size of the Board to 15 directors. In addition, the Company has also appointed Mr. Lin to the Board’s Nominating and Governance Committee as Vice Chair and to the Board’s Strategic Advisory Committee. Mr. Lin has been appointed to the Board pursuant to the Partnership Agreement between the Company and KKR. Per the Partnership Agreement, Mr.

   Read the 8-K filing
9. Apr 15, 2025

   On April 10, 2025, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Henry Schein, Inc. (the “Company”) approved the adoption of the Henry Schein, Inc. Executive Severance Plan (the “Severance Plan”), to provide severance benefits to certain executive-level employees in the event their employment with the Company terminates under certain qualifying circumstances, as further described below, and the adoption of the amended and restated Henry Schein, Inc. Executive Change in Control Plan (the “CIC Plan”), to provide for coordination of benefits with the Severance Plan and any other severance arrangements. Severance Plan The Severance Plan contains the following terms and conditions: • Eligibility and Participation .

   Read the 8-K filing
10. Mar 14, 2025

    On March 11, 2025, James P. Breslawski, President of Henry Schein, Inc. (the “Company”), informed the Company that effective as of April 1, 2025, he will transition out of the role of President of the Company. Effective as of that date, Mr. Breslawski will assume a new role with the Company as Senior Advisor and remain a member of the Company’s Executive Management Committee.

    Read the 8-K filing
11. Jan 29, 2025

    The information set forth under Item 1.01 of this Current Report on Form 8-K relating to the Changes to the Board is incorporated by reference herein. On January 27, 2025, Robert J. Hombach was appointed to the Board as a director. The Board has determined that Mr. Hombach satisfies the definition of an “independent director” as such term is defined in the rules and regulations of the Nasdaq Stock Market. In connection with the appointment of Mr. Hombach, the Company increased the size of the Board to 14 directors. Mr. Hombach is also expected to be appointed to the Board’s Strategic Advisory Committee. There are no arrangements or understandings between Mr. Hombach and any other person pursuant to which he was selected as a director. Mr. Hombach is not a party to any transaction subject to Section 404(a) of Regulation S-K involving the Company or any of its subsidiaries. Mr.

    Read the 8-K filing
12. May 24, 2024

    On May 21, 2024, at the Henry Schein, Inc. (the “Company”) 2024 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved the amendment and restatement of the Henry Schein, Inc. 2020 Stock Incentive Plan (the “2020 Stock Incentive Plan”), renamed the Henry Schein, Inc. 2024 Stock Incentive Plan (the “2024 Stock Incentive Plan”). The amendment and restatement incorporates the following changes: • Increase of the Aggregate Share Reserve . The aggregate share reserve was increased by an additional 4,800,000 shares of common stock for a maximum total share reserve of 75,742,657 shares of common stock under the 2024 Stock Incentive Plan, subject to antidilution adjustments set forth in the 2024 Stock Incentive Plan. • Increase of Individual Participant Limitations .

    Read the 8-K filing
13. Dec 18, 2023

    Appointment of Carole T. Faig as a Director On December 13, 2023, upon the recommendation of the Nominating and Governance Committee of the Board of Directors (the “Board”) of Henry Schein, Inc. (the “Company”), the Board increased the size of the Board to fifteen directors and appointed Carole T. Faig as a new independent director to fill the resulting vacancy, effective immediately. Prior to retiring in July 2021, from her 38-year career at Ernst & Young LLP (EY), Ms. Faig served in several leadership roles, including U.S. Health Leader and West Region Health and Life Sciences Leader, where she was responsible for developing and driving EY’s strategy to grow its health care practice in a rapidly changing environment. On December 18, 2023, the Company issued a press release announcing the appointment of Ms.

    Read the 8-K filing
14. Nov 16, 2023

    Amendment and Restatement of the Henry Schein, Inc. Deferred Compensation Plan On November 10, 2023, the Compensation Committee of the Board of Directors of Henry Schein, Inc. (the “Company”) approved the amendment and restatement of the Henry Schein, Inc. Deferred Compensation Plan (the “Plan”), effective as of November 14, 2023. The amendment and restatement incorporates the following changes: • Joint ventures and other entities owned 50% or more by the Company or its controlled group members are permitted to become participating employers in the Plan, subject to approval by the Company. • The eligible annual base compensation (as described in the Plan) threshold to make salary deferrals for plan years commencing with the 2024 Plan year is increased from $175,000 to $225,000.

    Read the 8-K filing
15. May 25, 2023

    On May 23, 2023, at the Henry Schein, Inc. (the “Company”) 2023 Annual Meeting of Stockholders (the “Annual Meeting”), the Company’s stockholders approved the amendment and restatement of the Henry Schein, Inc. 2015 Non-Employee Director Stock Incentive Plan, renamed the Henry Schein, Inc. 2023 Non-Employee Director Stock Incentive Plan (the “2023 Non-Employee Director Stock Incentive Plan”). The amendment and restatement incorporates the following changes: • Increase of the Aggregate Share Reserve . The aggregate share reserve was increased by an additional 275,000 shares of common stock for a maximum total share reserve of 2,075,000 shares of common stock under the 2023 Non-Employee Director Stock Incentive Plan, subject to antidilution adjustments set forth in the 2023 Non-Employee Director Stock Incentive Plan. • Clarification of “Acquisition Event” Provisions .

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.